Healthcare
Tarsus Pharmaceuticals, Inc.(TARS)
Live Price
Offline$63.16
+0.98% today
1Y Change
+55.38%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $2.71B
- Revenue Growth
- +146.7%
- EPS Growth
- +48.2%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tarsus Pharmaceuticals, Inc. (TARS) is a Healthcare stock with a market cap of $2.71B and listed on NASDAQ. The stock last traded around $63.16 and up 55.4% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +146.7%, EPS growth of +48.2%, a dividend yield of 0.0%. What stands out right now is revenue +146.7%, EPS +48.2%, free cash flow +73.6% with operating margin -15.7% and ROIC -16.6%. Valuation sits in the middle of the pack at price/sales 6.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TARS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+146.7% vs +7.6% peer median
Operating Margin
Below sector median
-15.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +146.7% and EPS at +48.2%, with operating margin around -15.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +6.3% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | -4.3% | +1.9% | -7.3% |
2026 Feb 23, 2026 | -94.2% | +7.8% | +11.3% | -7.8% |
2025 Nov 4, 2025 | +14.3% | -4.6% | +5.8% | +14.5% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TARS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TARS Max Drawdown
-30.42%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TARS and SPY.
Company Overview
Tarsus Pharmaceuticals, Inc.
NASDAQ Global Select
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
- Leadership
- Bobak R. Azamian
- IPO Date
- Oct 16, 2020
- Employees
- 323
- Street Address
- 15440 Laguna Canyon Road
- Mailing
- Irvine, CA, 92618
- Region
- Irvine, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 409 9820
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 6.0
- Price/Book
- 7.9
Growth
- Revenue
- +146.7%
- EPS
- +48.2%
- Free Cash Flow
- +73.6%
Profitability
- Gross Margin
- 89.6%
- Operating Margin
- -15.7%
- Net Margin
- -14.7%
- ROE
- -19.6%
- ROIC
- -16.6%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 3.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.